Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib

Video

In Partnership With:

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Agustin A. Garcia, MD, Associate Professor of Medicine, Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

This phase I/II trial analyzed the efficacy of the combination veliparib and carboplatin. The results of the phase I portion of the study were presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting. The phase II portion of the trial will compare veliparib alone to veliparib and chemotherapy.

PARP inhibitors are highly specific for patients who are BRCA carriers. Though the BRCA gene is associated with breast cancer and ovarian cancer risk, this trial was specific to patients with breast cancer. This trial determined the maximum tolerated dose of carboplatin in combination with veliparib. Treatment was well-tolerated.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD